Melior is Proud to Recognize Client Success
At Melior, we recognize the requirement of product value generation towards raising additional capital or achieving an exit. We further understand that until clinical proof-of-concept data is generated, in vivo model data is usually the most important value-add that a product receives. We carefully approach every study that we conduct for clients with this in mind, and we are thrilled (vicariously) when we see our clients achieve great success, especially in the event that the data we provided played a pivotal part.
The number of our studies that have been submitted to INDs, or contributed to pitch decks that got funded, is too numerous and hard-to-track here. Therefore, over the last ten years, we have begun to assemble a sort of “best of” list comprised of companies whom we have provided data to that were subsequently purchased by a larger company. In all cases, the acquisitions came within a year or two of the studies that we completed for that client and we are delighted if our contribution was an important part of the story.
While all the credit for these deals undoubtedly goes to the ingenuity and hard work of these management teams; we are nonetheless so proud to be part of the value generation from these multiple exits.
Let Melior help you extract the full value opportunity from your product.
Merck buys cancer therapy developer Modifi Biosciences for up to $1.3 bln
Modifi Biosciences was acquired by Merck in 2024 for $1.3 Bln.
October 23, 2024
Allergan Aesthetics to Acquire Soliton, Expanding Body Contouring Portfolio
Soliton was acquired by Allergan in 2021 for
$550 MM.
May 10, 2021
Amgen announces a recommended public cash offer to the shareholders of Nuevolution.
NuEvolution was acquired by Amgen in 2019 for $167 MM.
May 21, 2019
Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
Tolero was acquired by Sumitomo Dainippon in 2016 for $580 MM.
December 21, 2016